Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

This content was first published in Golf Journal, a quarterly print and monthly digital publication exclusively for USGA Members. To be among the first to receive Golf Journal and to learn how you can ...

Crew members on flotilla vessel Conscience after intercepted by Israeli forces A new flotilla heading for the Gaza Strip with food and medical supplies on board has been intercepted by Israeli forces.

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

Three Russian MiG-31 Foxhound fighters violated Estonian airspace, prompting the scramble of two Italian F-35s to intercept them. Three MiG-31 Foxhound fighters of the Russian Aerospace Forces entered ...

NATO jets intercepted two Russian SU-30 warplanes carrying supersonic missiles over the Baltic Sea as Vladimir Putin continues to taunt the West with aggressive shows of Moscow's military strength.

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily ...

My summer reading was a little unusual this year, because I’m in the middle of writing a book, which is orienting my reading choices (alongside my nagging insecurities, etc.) The book I’m writing is ...